结肠镜与胶囊粪菌移植治疗复发性艰难梭菌感染的有效性和安全性
这项多中心前瞻性真实世界队列纳入269例复发性艰难梭菌感染患者共301次粪菌移植,1个月和2个月治愈率分别为86%和81%,胶囊粪菌移植与结肠镜粪菌移植的1个月和2个月治愈率无差异;结肠镜相关严重不良事件为1例吸入性肺炎,未发现新的安全信号。
要点
- 胶囊粪菌移植与结肠镜粪菌移植1个月和2个月治愈率无差异。
- 1个月治愈率86%(95%CI 82%-90%),2个月治愈率81%(95%CI 75%-86%)。
- 高龄、血液透析及粪菌移植后使用抗生素与2个月粪菌移植失败相关。
核心结论
- 使用冻干胶囊的胶囊粪菌移植与结肠镜粪菌移植具有相似的安全性和有效性,且无结肠镜操作风险。
- 尽管总体高效,患者选择是优化粪菌移植成功的关键因素。
研究设计与样本
- 多中心、前瞻性、真实世界队列研究,在6个中心前瞻性登记复发性艰难梭菌感染患者粪菌移植后的临床结局和不良事件。
- 共对269例患者实施301次粪菌移植,使用的粪菌制剂为明尼苏达大学微生物治疗项目生产的两种标准化制剂之一:冻干/胶囊型或冷冻融化/液体型。
- 粪菌移植给药途径由治疗医生决定,在1个月和2个月评估治愈率,并在最初72小时内以及1个月和2个月收集安全性数据。
- 采用逻辑回归分析粪菌移植失败的相关因素。
主要发现
- 301次粪菌移植中三分之二为胶囊粪菌移植。
- 艰难梭菌感染治愈率在1个月为86%(95%CI 82%-90%),在2个月为81%(95%CI 75%-86%)。
- 胶囊粪菌移植与结肠镜粪菌移植的1个月或2个月治愈率无差异。
- 胶囊粪菌移植接受者年龄更大,且免疫抑制或炎症性肠病的可能性更低。
- 多因素逻辑回归显示,高龄和血液透析与2个月粪菌移植失败相关,粪菌移植后使用抗生素也与2个月粪菌移植失败相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) emerged as rescue treatment for multiply recurrent Clostridioides difficile infections (rCDIs) nonresponsive to standard therapy. However, estimation of FMT efficacy varies among different protocols and formulations, while placebo-controlled clinical trials have excluded most rCDI patients because of medical comorbidities. This study aimed to determine the safety and effectiveness of capsule FMT (cap-FMT) and colonoscopy FMT (colo-FMT) for rCDI using standardized products in a large, multicenter, prospective, real-world cohort. METHODS: Clinical outcomes and adverse events after FMT performed for rCDI at 6 sites were captured in a prospective registry. FMT was performed using 1 of 2 standardized formulations of microbiota manufactured by the University of Minnesota Microbiota Therapeutics Program, freeze-dried/encapsulated or frozen-thawed/liquid. The FMT administration route was determined by the treating physician. The rCDI cure rate was assessed at 1 and 2 months. Safety data were collected within the first 72 hours and at 1 and 2 months. Logistic regression was used to investigate factors associated with FMT failure. RESULTS: A total of 301 FMTs were performed in 269 unique patients. Two-thirds were cap-FMT. CDI cure rates were 86% (95% CI, 82%-90%) at 1 month and 81% (95% CI, 75%-86%) at 2 months. There was no difference in the 1-month or 2-month cure rate between cap-FMT and colo-FMT. Cap-FMT recipients were older and less likely to be immunosuppressed or have inflammatory bowel disease. Patient factors of older age and hemodialysis were associated with FMT failure by 2 months on multivariate logistic regression. In addition, post-FMT antibiotic use was associated with FMT failure at 2 months. One serious adverse event was related to colonoscopy (aspiration pneumonia), otherwise no new safety signals were identified. CONCLUSIONS: Cap-FMT using freeze-dried capsules has a similar safety and effectiveness profile compared with colo-FMT, without the procedural risks of colonoscopy. Although highly effective overall, patient selection is a key factor to optimizing FMT success.
引用
- Vaughn BP, Fischer M, Kelly CR, et al. Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Clin Gastroenterol Hepatol. 2022. PMID: 36126907. doi:10.1016/j.cgh.2022.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。